Outlook Therapeutics Inc (OTLK)

[thermo]

Analyst increases price target:

https://www.tipranks.com/news/article/outlook-therapeutic-stock-set-to-see-big-gains-says-analyst/

What I find interesting is that Tsao (HCW analyst) gets to a $6 target with only an 80% probability of FDA approval. I was at 80% before the latest data release. So, a crude estimate of a target price with approval would be $6/0.8 => $7.5.

I see even more upside once the market understands (a) pre filled syringe packaging will make this a big product (b) the market is so big that it's easy to get to $1B in revs even with Eyelea coming off patent, (c) only a moderate sized sales force is needed to market, (d) they will probably never get to build a sales force because companies that already have ophthalmic sales forces will find this too compelling.

But, I may want to buy more, so PLEASE DON'T BUY OTLK.